Ozempic might be fighting cancer too, real-world data from…

Ozempic might be fighting cancer too, real-world data from 12,000 patients is hard to ignore GLP-1 drugs were prescribed for weight and blood sugar. New ASCO 2026 data shows they may be cutting metastatic cancer progression by up to 50% in four major cancer types. Nobody prescribed semaglutide to treat cancer. And yet, here we are. Real-world data presented today at ASCO 2026, drawn from 12,112 patients shows that GLP-1 receptor agonists significantly reduce metastatic progression in stage I–III lung, breast, colorectal, and liver cancers.